Case reports of serious Andexxa side effects, deep vein thrombosis (DVT) and pulmonary embolism (PE), resulted in the FDA starting a drug safety investigation in November 2024. The issue was whether there was an apparent increased rate of Andexxa-related blood clots, which can lead to DVT and/or PE, as well as clotting-related deaths, compared with … [Read more...]
Andexxa Risks Outweigh Its Benefits, Says FDA In December 2025
When AstraZeneca asserted that their recent Andexxa drug recall had to do with “commercial reasons”, we suggested that there was an Andexxa drug safety issue involved, also, in our December 15, 2025, Drug Injury Watch post, "Andexxa Drug Recall December 2025 Due In Part To Safety Issue That Involves Blood Clots". And this December 18, 2025, FDA … [Read more...]
Andexxa Drug Injury Lawsuits for Blood Clots, PE, DVT
Andexxa (andexanet) is a treatment currently used when the reversal of anticoagulation is needed for life-threatening or uncontrolled bleeding in patients who are using Eliquis (apixaban) or Xarelto (rivaroxaban) at the time. Andexxa drug injury lawsuits for patients who developed blood clots involving a pulmonary embolism (PE) or deep vein … [Read more...]
Andexxa Clotting-Related Deaths and Andexxa Blood Clots
The FDA’s Cellular, Tissue, and Gene Therapies Advisory Committee recently discussed the increased risk of Andexxa clotting-related deaths and Andexxa blood clots seen in the ANNEXA-I trial done for Andexxa, compared with a standard of care reversal agent. This Andexxa Advisory Committee considered the current drug safety profile of Andexxa in … [Read more...]